Strides Pharma Science Limited, who’s a pharmaceutical company. It’s headquartered is in Bangalore. They will seek approval from the Central Drug Standard Control Organization to sell Favipiravir tablets in India.
Favipiravir tablets is an antiviral medication, it is used to treat influenza in Japan. Strides Pharma already developed and commercialized this tablet and this will export in three different countries from the Gulf Cooperation Council (GCC).
Strides Pharma said “The product is currently being exported to GCC countries to treat patients under their treatment program for Covid-19. Strides will also immediately apply to Indian Drug Authorities to commence necessary studies and make the drug available to Indian patients expeditiously.”
China and many other countries showed that this drug has some positive outcomes, including infection duration of Covid-19 and also improve lungs condition in the patients.
R Ananthanarayanan, chief executive officer and managing director of Strides Pharma said: “Favipiravir is a complex drug to make, while we are manufacturing the tablets in-house, we are also excited to partner with the API manufacturer such that our supply chain remains secured up to the key starting material.”
The company didn’t give details on which three of the six GCC countries it will be exported.
Strides have developed this tablet in 400 mg and 200 mg strength for dosage administration.
A spokesperson of Strides Pharma told that the company has not received approval from US food and drug administration (FDA).
